Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$7.03 - $11.07 $98,420 - $154,980
-14,000 Reduced 97.22%
400 $2,000
Q4 2023

Feb 14, 2024

BUY
$6.25 - $11.11 $90,000 - $159,984
14,400 New
14,400 $145,000
Q1 2023

May 12, 2023

BUY
$7.03 - $11.53 $120,255 - $197,232
17,106 New
17,106 $124,000
Q3 2022

Nov 07, 2022

BUY
$12.16 - $19.42 $177,973 - $284,231
14,636 New
14,636 $179,000
Q2 2022

Aug 09, 2022

SELL
$9.99 - $21.35 $23,506 - $50,236
-2,353 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$14.08 - $27.63 $33,130 - $65,013
2,353 New
2,353 $44,000
Q2 2021

Aug 12, 2021

SELL
$31.29 - $56.64 $248,067 - $449,041
-7,928 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$39.71 - $90.58 $307,673 - $701,813
7,748 Added 4304.44%
7,928 $332,000
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $4,872 - $15,182
180 New
180 $12,000
Q3 2020

Nov 16, 2020

SELL
$28.06 - $37.16 $4,601 - $6,094
-164 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$18.5 - $34.34 $3,034 - $5,631
164 New
164 $4,000
Q1 2020

May 13, 2020

SELL
$14.88 - $32.78 $55,056 - $121,286
-3,700 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$19.49 - $32.63 $58,469 - $97,890
3,000 Added 428.57%
3,700 $109,000
Q3 2019

Nov 12, 2019

BUY
$22.49 - $26.81 $15,742 - $18,767
700 New
700 $15,000
Q3 2018

Nov 13, 2018

SELL
$27.65 - $38.39 $202,812 - $281,590
-7,335 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$31.4 - $41.01 $168,178 - $219,649
5,356 Added 270.64%
7,335 $262,000
Q1 2018

May 11, 2018

BUY
$29.84 - $44.08 $59,053 - $87,234
1,979 New
1,979 $65,000
Q4 2017

Feb 12, 2018

SELL
$21.89 - $31.34 $108,289 - $155,038
-4,947 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$15.81 - $24.01 $78,212 - $118,777
4,947
4,947 $118,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.